Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “BRAF Mutant Metastatic Melanoma”

48 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 48 results

Early research (Phase 1)Ended earlyNCT01611675
What this trial is testing

Leflunomide+Vemurafenib in V600 Mutant Met. Melanoma

Who this might be right for
Melanoma
Massachusetts General Hospital 3
Testing effectiveness (Phase 2)Active Not RecruitingNCT04417621
What this trial is testing

Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma

Who this might be right for
Melanoma
Novartis Pharmaceuticals 134
Early research (Phase 1)Study completedNCT03864042
What this trial is testing

Pharmacokinetic Drug-drug Interaction Study of Encorafenib and Binimetinib on Probe Drugs in Patients With BRAF V600-mutant Melanoma or Other Advanced Solid Tumors

Who this might be right for
Advanced Solid TumorsMetastatic Melanoma
Pfizer 56
Early research (Phase 1)Ended earlyNCT01940809
What this trial is testing

Ipilimumab With or Without Dabrafenib, Trametinib, and/or Nivolumab in Treating Patients With Melanoma That Is Metastatic or Cannot Be Removed by Surgery

Who this might be right for
BRAF V600E Mutation PresentBRAF V600K Mutation PresentMetastatic Melanoma+5 more
National Cancer Institute (NCI) 15
Testing effectiveness (Phase 2)UnknownNCT04720768
What this trial is testing

Encorafenib, Binimetinib and Palbociclib in BRAF-mutant Metastatic Melanoma CELEBRATE

Who this might be right for
MelanomaMetastasis
Peter MacCallum Cancer Centre, Australia 78
Early research (Phase 1)Looking for participantsNCT05538130
What this trial is testing

Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors

Who this might be right for
MelanomaGliomaThyroid Cancer+10 more
Pfizer 124
Early research (Phase 1)Ended earlyNCT02097225
What this trial is testing

Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

Who this might be right for
BRAF V600E Mutation PresentBRAF V600K Mutation PresentMetastatic Malignant Solid Neoplasm+7 more
National Cancer Institute (NCI) 22
Testing effectiveness (Phase 2)Study completedNCT01902173
What this trial is testing

Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer

Who this might be right for
Hematopoietic and Lymphoid Cell NeoplasmLocally Advanced Malignant Solid NeoplasmLocally Advanced Melanoma+6 more
National Cancer Institute (NCI) 27
Testing effectiveness (Phase 2)Study completedNCT01512251
What this trial is testing

BKM120 Combined With Vemurafenib (PLX4032) in BRAFV600E/K Mutant Advanced Melanoma

Who this might be right for
BRAF Mutant Metastatic Melanoma
University of California, San Francisco 8
Early research (Phase 1)Study completedNCT01436656
What this trial is testing

A Phase I Study of Oral LGX818 in Adult Patients With Advanced or Metastatic BRAF Mutant Melanoma

Who this might be right for
Melanoma and Metastatic Colorectal Cancer
Pfizer 107
Testing effectiveness (Phase 2)Study completedNCT02902042
What this trial is testing

Encorafenib + Binimetinib + Pembrolizumab in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma

Who this might be right for
Malignant Melanoma
Prof. Dr. med. Dirk Schadendorf 16
Testing effectiveness (Phase 2)Ended earlyNCT04655157
What this trial is testing

Safety and Efficacy in Participants With Metastatic BRAF-mutant Melanoma Treated With Encorafenib With and Without Binimetinib in Combination With Nivolumab and Low-dose Ipilimuma

Who this might be right for
Melanoma
Jason J. Luke, MD 2
Early research (Phase 1)Study completedNCT05003622
What this trial is testing

Phase 1 Safety Study of Encorafenib in Chinese Patients With Advanced Metastatic BRAF V600E Mutant Solid Tumors

Who this might be right for
BRAF V600E Unresectable or Metastatic MelanomaBRAF V600E Metastatic NSCLCMelanoma
Pierre Fabre Medicament 3
Testing effectiveness (Phase 2)Study completedNCT01726738
What this trial is testing

LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional Mutations

Who this might be right for
Stage III MelanomaStage IV MelanomaUnresectable Melanoma+1 more
UNC Lineberger Comprehensive Cancer Center 17
Large-scale testing (Phase 3)Study completedNCT01227889
What this trial is testing

A Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma

Who this might be right for
Cancer
GlaxoSmithKline 251
Large-scale testing (Phase 3)Study completedNCT01584648
What this trial is testing

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Who this might be right for
Melanoma
Novartis Pharmaceuticals 423
Testing effectiveness (Phase 2)Ended earlyNCT01777776
What this trial is testing

Safety and Efficacy of LEE011 and LGX818 in Patients With BRAF Mutant Melanoma.

Who this might be right for
Locally Advanced Metastatic BRAF Mutant Melanoma
Array BioPharma 28
Early research (Phase 1)Ended earlyNCT03878719
What this trial is testing

Study of the Combination of Binimetinib and Encorafenib in Adolescent Patients With Unresectable or Metastatic BRAF V600-mutant Melanoma

Who this might be right for
Melanoma
Pfizer 1
Large-scale testing (Phase 3)Study completedNCT01245062
What this trial is testing

GSK1120212 vs Chemotherapy in Advanced or Metastatic BRAF V600E/K Mutation-positive Melanoma

Who this might be right for
Melanoma
GlaxoSmithKline 322
Testing effectiveness (Phase 2)Ended earlyNCT01519427
What this trial is testing

Selumetinib and Akt Inhibitor MK2206 in Treating Patients With Stage III or Stage IV Melanoma Who Failed Prior Therapy With Vemurafenib or Dabrafenib

Who this might be right for
Recurrent MelanomaStage IIIA MelanomaStage IIIB Melanoma+2 more
National Cancer Institute (NCI) 2
Load More Results